Return to Clinical Trials Search Results

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Primary Objectives: To centrally test resected NSCLC for genetic mutations to facilitate accrual to randomized adjuvant studies. To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow clinically annotated advanced genomic analyses in concert with the NCI Center for Cancer Genomics (CCG). Secondary Objectives: To characterize the natural history of molecularly characterized NSCLC to allow subsequent development of targeted therapies against genotype-defined subpopulations in the adjuvant and recurrent settings. To cross-validate local genotyping assays for EGFR and ALK with a central reference standard. Exploratory Objectives: To study the genomic evolution of lung cancers by comparing genomic characteristics at resection and at recurrence. To understand reasons behind lack of enrollment to adjuvant targeted therapy studies for potentially eligible patients. To study the clinical significance of circulating tumor DNA within the plasma cell-free DNA (cfDNA) from early stage lung cancer patients.

Primary Objectives: To centrally test resected NSCLC for genetic mutations to facilitate accrual to randomized adjuvant studies. To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to allow clinically annotated advanced genomic analyses in concert with the NCI Center for Cancer Genomics (CCG). Secondary Objectives: To characterize the natural history of molecularly characterized NSCLC to allow subsequent development of targeted therapies against genotype-defined subpopulations in the adjuvant and recurrent settings. To cross-validate local genotyping assays for EGFR and ALK with a central reference standard. Exploratory Objectives: To study the genomic evolution of lung cancers by comparing genomic characteristics at resection and at recurrence. To understand reasons behind lack of enrollment to adjuvant targeted therapy studies for potentially eligible patients. To study the clinical significance of circulating tumor DNA within the plasma cell-free DNA (cfDNA) from early stage lung cancer patients.